Polysaccharides for colon targeted drug delivery

被引:241
作者
Chourasia, MK [1 ]
Jain, SK [1 ]
机构
[1] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Pharmaceut Res Projects Lab, Sagar 470003, MP, India
关键词
biodegradable hydrogels; biodegradable polymers; colon targeted drug delivery; colonic microflora; polysaccharides;
D O I
10.1080/10717540490280778
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Colon targeted drug delivery has the potential to deliver bioactive agents for the treatment of a variety of colonic diseases and to deliver proteins and peptides to the colon for their systemic absorption. Various strategies, currently available to target the release of drugs to colon, include formation of prodrug, coating of pH-sensitive polymers, use of colon-specific biodegradable polymers, timed released systems, osmotic systems, and pressure controlled drug delivery systems. Among the different approaches to achieve targeted drug release to the colon, the use of polymers especially biodegradable by colonic bacteria holds great promise. Polysaccharidases are bacterial enzymes that are available in sufficient quantity to be exploited in colon targeting of drugs. Based on this approach, various polysaccharides have been investigated for colon-specific drug release. These polysaccharides include pectin, guar gum, amylose, inulin, dextran, chitosan, and chondroitin sulphate. This family of natural polymers has an appeal to drug delivery as it is comprised of polymers with a large number of derivatizable groups, a wide range of molecular weights, varying chemical compositions, and, for the most part, low toxicity and biodegradability yet high stability. The most favorable property of these materials is their approval as pharmaceutical excipients.
引用
收藏
页码:129 / 148
页数:20
相关论文
共 187 条
[1]   BREAKDOWN OF DEXTRAN BY HUMAN FECES [J].
ABERG, B .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1953, 5 (01) :37-38
[2]   The use of scintigraphy to provide ''proof of concept'' for novel polysaccharide preparations designed for colonic drug delivery [J].
Adkin, DA ;
Kenyon, CJ ;
Lerner, EI ;
Landau, I ;
Strauss, E ;
Caron, D ;
Penhasi, A ;
Rubinstein, A ;
Wilding, IR .
PHARMACEUTICAL RESEARCH, 1997, 14 (01) :103-107
[3]   Influence of neutron activation factors on matrix tablets for site specific delivery to the colon [J].
Ahrabi, SF ;
Heinämäki, J ;
Sande, SA ;
Graffner, C .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 10 (03) :225-235
[4]   Development of pectin matrix tablets for colonic delivery of model drug ropivacaine [J].
Ahrabi, SF ;
Madsen, G ;
Dyrstad, K ;
Sande, SA ;
Graffner, C .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 10 (01) :43-52
[5]  
Aiedeh K, 1999, ARCH PHARM, V332, P103, DOI 10.1002/(SICI)1521-4184(19993)332:3<103::AID-ARDP103>3.0.CO
[6]  
2-U
[7]   PREPARATION AND EVALUATION OF CROSS-LINKED CHITOSAN MICROSPHERES CONTAINING FUROSEMIDE [J].
AKBUGA, J ;
DURMAZ, G .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 111 (03) :217-222
[8]   UTILIZATION OF SCHARDINGER DEXTRINS BY RAT [J].
ANDERSEN, GH ;
ROBBINS, FM ;
LONG, CL ;
DOMINGUES, FJ ;
MOORES, RG .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1963, 5 (02) :257-&
[9]  
[Anonymous], 1992, PHARM RES
[10]   ENZYMATIC DEGRADATION OF ALPHA-CYCLODEXTRINS AND BETA-CYCLODEXTRINS BY BACTEROIDES OF THE HUMAN-COLON [J].
ANTENUCCI, RN ;
PALMER, JK .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 1984, 32 (06) :1316-1321